{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:56Z","timestamp":1792511936970,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,6,10]]},"abstract":"\n Importance<\/jats:title>\n Uptake of recommended seasonal influenza and COVID-19 vaccines remains suboptimal.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the immunogenicity and safety of an investigational mRNA-1083 vaccine against seasonal influenza and SARS-CoV-2 in adults 50 years and older.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This phase 3, randomized, observer-blinded trial was conducted across 146 US sites in adults 50 years and older enrolled between October 19, 2023, and November 21, 2023. Data extraction was complete on April 9, 2024.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants in 2 age cohorts (\u226565 years and 50-64 years) were randomly assigned (1:1) to receive mRNA-1083 plus placebo or coadministered licensed quadrivalent seasonal influenza (\u226565 years: high-dose quadrivalent inactivated influenza vaccine [HD-IIV4]; 50-64 years: standard-dose IIV4 [SD-IIV4]) and COVID-19 (all ages: mRNA-1273) vaccines.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary objectives were to demonstrate the noninferiority of humoral immune responses following mRNA-1083 vs comparators against vaccine-matched strains at day 29 and to evaluate the reactogenicity and safety of mRNA-1083. Secondary objectives included demonstration of superiority of humoral immune responses elicited by mRNA-1083 relative to comparators at day 29.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, 8015 participants were enrolled and vaccinated (4017 aged \u226565 y and 3998 aged 50-64 y). Among adults 65 years and older and 50 to 64 years, the median age was 70 and 58 years, 54.2% and 58.8% were female, 18.4% and 26.7% were Black or African American, and 13.9% and 19.3% were Hispanic or Latino, respectively. Noninferior immunogenicity of mRNA-1083 was demonstrated against all vaccine-matched influenza and SARS-CoV-2 strains based on lower bound of the 97.5% CI of the geometric mean ratio greater than 0.667 and lower bound of the 97.5% CI of the seroconversion\/seroresponse rate difference greater than \u221210%. mRNA-1083 elicited higher immune responses than SD-IIV4 (50-64 years) for all 4 influenza strains and HD-IIV4 (\u226565 years) for 3 influenza strains (A\/H1N1, A\/H3N2, B\/Victoria) and against SARS-CoV-2 (all ages). Solicited adverse reactions were numerically higher in frequency and severity after mRNA-1083 vaccination than comparators in both age cohorts (\u226565 y: 83.5% and 78.1%; 50-64 y: 85.2% and 81.8%); most were grade 1 or 2 in severity and of short duration. No safety concerns were identified.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, mRNA-1083 met noninferiority criteria and induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all 4 influenza strains (among those ages 50-64 y), the 3 clinically relevant influenza strains (among those aged \u226565 y), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT06097273<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2025.5646","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T11:54:26Z","timestamp":1746618866000},"page":"1977","source":"Crossref","is-referenced-by-count":49,"title":["Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults \u226550 Years"],"prefix":"10.1001","volume":"333","author":[{"given":"Amanda K.","family":"Rudman Spergel","sequence":"first","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Wu","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Deng","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Cardona","sequence":"additional","affiliation":[{"name":"Indago Research and Health Center, Hialeah, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimball","family":"Johnson","sequence":"additional","affiliation":[{"name":"CenExel iResearch, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Espinosa-Fernandez","sequence":"additional","affiliation":[{"name":"Revival Research Corporation, Doral, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Sinkiewicz","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Urdaneta","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizbeth","family":"Carmona","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Schaefers","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Girard","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamuna D.","family":"Paila","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshan","family":"Mehta","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Callendret","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusine","family":"Kostanyan","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintanat","family":"Ananworanich","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Miller","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Das","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10440","key":"joi250026r1","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","author":"GBD 2021 Diseases and Injuries Collaborators","year":"2024","journal-title":"Lancet"},{"issue":"19","key":"joi250026r2","first-page":"185","article-title":"Vaccines against influenza: WHO position paper\u2014May 2022.","volume":"97","author":"World Health Organization","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"issue":"10440","key":"joi250026r4","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","author":"GBD 2021 Causes of Death Collaborators","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"joi250026r6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/vaccines12020216","article-title":"Co-administration of influenza and COVID-19 vaccines: policy review and vaccination coverage trends in the European Union, UK, US, and Canada between 2019 and 2023.","volume":"12","author":"Achterbergh","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"joi250026r11","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2195786","article-title":"Vaccine co-administration in adults: an effective way to improve vaccination coverage.","volume":"19","author":"Bonanni","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"joi250026r12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged =65 years: a phase 2, randomised, open-label study.","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"2","key":"joi250026r13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"10318","key":"joi250026r14","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","article-title":"Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.","volume":"398","author":"Lazarus","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"joi250026r15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2327736","article-title":"No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: a randomized trial.","volume":"20","author":"Naficy","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"joi250026r16","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2131166","article-title":"Coadministration of seasonal influenza and COVID-19 vaccines: a systematic review of clinical studies.","volume":"18","author":"Janssen","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"joi250026r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126847","article-title":"A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.","volume":"50","author":"Soens","year":"2025","journal-title":"Vaccine"},{"key":"joi250026r21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03591-0","article-title":"mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1\/2 trial.","author":"Rudman Spergel","journal-title":"Nat Med"},{"issue":"7","key":"joi250026r22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jval.2020.03.003","article-title":"Estimation of an instrument-defined minimally important difference in EQ-5D-5L index scores based on scoring algorithms derived using the EQ-VT Version 2 valuation protocols.","volume":"23","author":"Henry","year":"2020","journal-title":"Value Health"},{"issue":"3","key":"joi250026r24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/cid\/ciac653","article-title":"Influenza during the 2010-2020 decade in the United States: seasonal outbreaks and vaccine interventions.","volume":"76","author":"Malosh","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"joi250026r25","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1093\/infdis\/jiae329","article-title":"Safety and immunogenicity of mRNA-1010, an investigational seasonal influenza vaccine, in healthy adults: final results from a phase 1\/2 randomized trial.","volume":"231","author":"Ananworanich","year":"2025","journal-title":"J Infect Dis"},{"issue":"1","key":"joi250026r26","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2336357","article-title":"Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines.","volume":"20","author":"Russell","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"joi250026r27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1128\/CVI.00604-15","article-title":"Correlates of protection against influenza in the elderly: results from an influenza vaccine efficacy trial.","volume":"23","author":"Dunning","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"joi250026r28","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/21645515.2017.1413518","article-title":"The establishment of surrogates and correlates of protection: useful tools for the licensure of effective influenza vaccines?","volume":"14","author":"Ward","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"joi250026r29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41467-022-35768-3","article-title":"Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial.","volume":"14","author":"Fong","year":"2023","journal-title":"Nat Commun"},{"issue":"692","key":"joi250026r30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade9078","article-title":"Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial.","volume":"15","author":"Benkeser","year":"2023","journal-title":"Sci Transl Med"},{"issue":"10","key":"joi250026r31","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3390\/v15102029","article-title":"Stochastic interventional vaccine efficacy and principal surrogate analyses of antibody markers as correlates of protection against symptomatic COVID-19 in the COVE mRNA-1273 trial.","volume":"15","author":"Huang","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"joi250026r32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31266","article-title":"Safety, reactogenicity, and health-related quality of life after trivalent adjuvanted vs trivalent high-dose inactivated influenza vaccines in older adults: a randomized clinical trial.","volume":"4","author":"Schmader","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"joi250026r33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s41687-022-00528-w","article-title":"Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients.","volume":"6","author":"Di Fusco","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"joi250026r18","author":"Chalkias","year":"2024"},{"key":"joi250026r3","unstructured":"Centers for Disease Control and Prevention. RESP-NET Interactive Dashboard (2023-24 season). Updated June 7, 2024. Accessed April 8, 2025. https:\/\/www.cdc.gov\/resp-net\/dashboard\/index.html"},{"key":"joi250026r5","unstructured":"Havers? FP. COVID-19-associated hospitalizations among infants, children and adults\u2014COVID-NET, January-August 2023. Centers for Disease Control and Prevention. September 12, 2023. Accessed February 29, 2024. https:\/\/stacks.cdc.gov\/view\/cdc\/132883"},{"key":"joi250026r7","unstructured":"Centers for Disease Control and Prevention. Weekly flu vaccination dashboard (2023-24 season). Updated May 24, 2024. Accessed April 8, 2025. https:\/\/www.cdc.gov\/fluvaxview\/dashboard\/index.html"},{"key":"joi250026r8","unstructured":"Centers for Disease Control and Prevention. Weekly COVID-19 vaccination dashboard (2023-24 season). Updated May 22, 2024. Accessed April 8, 2025. https:\/\/www.cdc.gov\/covidvaxview\/weekly-dashboard\/index.html"},{"key":"joi250026r9","unstructured":"World Health Organization. Interim recommendations for the use of mRNA COVID-19 vaccines. July 19, 2023. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-2023.1"},{"key":"joi250026r10","unstructured":"Centers for Disease Control and Prevention. What to Know About Getting Flu, COVID-19, and RSV Vaccines at the Same Time. November 2, 2023. Accessed April 8, 2025. https:\/\/www.cdc.gov\/ncird\/whats-new\/getting-vaccines-at-same-time.html"},{"key":"joi250026r17","unstructured":"Poulos? CMA, Kent? C, . Preferences for a combination influenza and COVID-19 vaccine: results from a threshold technique study with consumers in the United Kingdom. Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024. https:\/\/www.ispor.org\/docs\/default-source\/intl2024\/6691poulos-tt-ukispor-poster8apr2024-1137153-pdf.pdf?sfvrsn=2f35e01a_0"},{"key":"joi250026r19","unstructured":"Moderna? I. Moderna announces positive phase 3 efficacy data for mRNA-1283, the company\u2019s next generation COVID-19 vaccine. June 13, 2024. Accessed April 8, 2025. https:\/\/news.modernatx.com\/news\/news-details\/2024\/Moderna-Announces-Positive-Phase-3-Efficacy-Data-for-mRNA-1283-the-Companys-Next-Generation-COVID-19-Vaccine\/default.aspx"},{"key":"joi250026r23","unstructured":"World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. Updated February 23, 2024. Accessed March 12, 2024. https:\/\/www.who.int\/publications\/m\/item\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2833668\/jama_rudman_spergel_2025_oi_250026_1748540680.37736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:00:49Z","timestamp":1749553249000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2833668"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":33,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,6,10]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.5646","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}